Trastuzumab beyond progression: A challenge to translational oncology?

Annals of Oncology

Volumn 21, Issue 11, 2010, Pages 2131-2134

  Santoro, A ^a   Gullo, G ^b  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; LAPATINIB; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB;

BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CLINICAL TRIAL; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; EDITORIAL; HUMAN; METASTASIS; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; MEDICAL ONCOLOGY; RECEPTOR, ERBB-2; TRANSLATIONAL RESEARCH;

EID: 77958486939     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq410     Document Type: Editorial

References (22)

1. Baselga J, Tripathy D, Mendelsohn J et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996; 14: 737-744.
2. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
3. Marty M, Cognetti F, Maraninchi D et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005; 23: 4265-4274.
4. A Study of herceptin (Trastuzumab) in combination with 2nd-line chemotherapy in patients with HER2 positive metastatic breast cancer. http://www.clinicaltrials/ct2/show/NCT00444587 (22 May 2010, date last accessed).
5. THOR Study: a study of continued herceptin (Trastuzumab) in combination with second line chemotherapy in patients with HER2 positive metastatic breast cancer. http://www.clinicaltrials.gov/ct2/show/NCT00448279 (22 May 2010, date last accessed).
6. Trastuzumab Optimization Trial in Breast Cancer (TOP). http://www.clinicaltrials.gov/ct2/show/NCT00637325 (22 May 2010, date last accessed).
7. Benefit of adding trastuzumab to second line chemotherapy in breast cancer patients previously treated with trastuzumab. http://www.linicaltrials.gov/ct2/show/NCT00130507 (22 May 2010, date last accessed).
8. Vinorelbine with or without trastuzumab in treating women with progressive metastatic breast cancer. http://www.clinicaltrials.gov/ct2/show/NCT00103233 (22 May 2010, date last accessed).
9. von Minckwitz G, du Bois A, Schmidt M et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05 Study. J Clin Oncol 2009; 27: 1999-2006.
10. Grothey A, Sugrue MM, Purdie DM et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008; 26: 5326-5334.
11. Giantonio BJ. Targeted therapies: Goldie-Coldman and bevacizumab beyond disease progression. Nat Rev Clin Oncol 2009; 6: 311-312.
12. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733-2743.
13. Cameron D, Casey M, Press M et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008; 112: 533-543.
14. Blackwell KL, Burstein HJ, Storniolo AM et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumabrefractory metastatic breast cancer. J Clin Oncol 2010; 28: 1124-1130.
15. Pegram MD, Konecny GE, O'Callaghan C et al. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004; 96: 739-749.
16. Nahta R, Esteva FJ. In vitro effects of trastuzumab and vinorelbine in trastuzumab-resistant breast cancer cells. Cancer Chemother Pharmacol 2004; 53: 186-190.
17. Fujimoto-Ouchi K, Sekiguchi F, Yamamoto K et al. Preclinical study of prolonged administration of trastuzumab as combination therapy after disease progression during trastuzumab monotherapy. Cancer Chemother Pharmacol 2010; 66: 269-276.
18. Matter-Walstra KW, Dedes KJ, Schwenkglenks M et al. Trastuzumab beyond progression: a cost-utility analysis. Ann Oncol 2010; 21: 2161-2168.
19. Dedes KJ, Matter-Walstra KW, Schwenkglenks M et al. Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation. Eur J Cancer 2009; 45: 1397-1406.
20. Le QA, Hay JW. Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer. Cancer 2009; 115: 489-498.
21. Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2009; 27: 5838-5847.
22. Pohlmann PR, Mayer IA, Mernaugh R. Resistance to Trastuzumab in Breast Cancer. Clin Cancer Res 2009; 15: 7479-7491.